XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Nature of Business, Merger and Basis of Presentation (Details)
 3 Months Ended
Jan. 04, 2018
$ / shares
shares
Mar. 31, 2018
Program
Platform
$ / shares
Dec. 31, 2017
$ / shares
Business Acquisition [Line Items]      
Number of programs currently undergoing clinical testing targeting Fanconi Anemia | Program   2  
Number of additional programs in preclinical stages targeting other rare genetic diseases | Program   3  
Estimated period to file an investigational new drug application   12 months  
Number of technology platforms designed in collaboration with academic and industry partners | Platform   2  
Common stock, par value (in dollars per share) | $ / shares   $ 0.01 $ 0.01
Common Stock [Member]      
Business Acquisition [Line Items]      
Ownership percentage held by parent on fully diluted basis 81.357%    
Inotek [Member] | Common Stock [Member]      
Business Acquisition [Line Items]      
Number of shares received pursuant to merger agreement (in shares) | shares 76.185    
Common stock, par value (in dollars per share) | $ / shares $ 0.01    
Non-controlling interest, ownership percentage on fully diluted basis 18.643%